The Clorox Company (CLX)

Rating: HOLD

HOLD (5-tier) · income compounder · conviction: low

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-26. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -15% vs spot
• DCF fair value implies -29% vs spot — but this is terminal-value sensitive (exit-multiple $69 vs Gordon $108, 57% apart), so it carries less weight
• Bear case (Structural — Private-Label / Brand Erosion) downside is -55% vs spot
• Net: reward/risk of 0.3× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $95.44 (26 June 2026) Clorox trades on 15.1x forward earnings against a household-staples peer median of 23.6x. The market is paying peer multiples for Colgate and Church & Dwight while treating Clorox's $6.8bn revenue base as ex-growth, with a 5.2% dividend yield signalling doubt about payout durability against $3.3bn of net debt. The engine's view is more balanced but not constructive. The probability-weighted target of $94.50 sits level with spot, Monte Carlo puts only 39.6% of outcomes above the current price, and the anchors disagree sharply: the capex-bridge DCF at a 13x terminal multiple gives $69.38, the Gordon variant $108.83, and peer cross-reads imply $148.55 to $187.57. That dispersion, plus a 20% weight on structural brand erosion, is why the rating is HOLD rather than a contrarian valuation-gap trade. The single most damaging risk is private-label substitution compressing earnings and the multiple together, which is what drives the $43.85 structural target below the 52-week low of $84.70.

The dashboard below is the whole argument on one page: spot ($97) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural bear carries 20% weight and a coherent mechanism. Clorox's core categories — bleach, trash bags, wipes, charcoal — are functionally commoditised; private label matches performance at a visible shelf-price discount, and retailers have every incentive to push it as consumers trade down. Post-inflation pricing rebuilt margin but shed volume, and once the pricing lever is exhausted the arithmetic turns: negative volume, mix erosion and promotional re-investment push the operating margin toward 9.5% while revenue contracts around 5% a year. With $3.3bn of net debt and a dividend consuming most of free cash flow, the balance sheet offers no offset. Earnings and the multiple then de-rate together, which is how the $43.85 structural target lands below the 52-week low.

Key Debate

Gross Margin explains 55% of Monte Carlo outcome variance — the single variable that decides which side is right.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.51 vs analyst floor +0.05 → delta +0.46 (n=23 mgmt / 28 Q&A; 64th pctile across the S&P book, z +0.4).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1000 articles): avg ticker sentiment +0.02 (bullish 16% / bearish 11%)

Scenario Analysis

The tree runs from a structural 'Structural — Private-Label / Brand Erosion' downside ($44) to a 'Bull — Defensive Re-Rate' bull case ($150); the probability-weighted blend (PWEV $94) is -3% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Private-Label / Brand Erosion (20%, $44). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 43.85; probability: 0.2.
• Consumer / Input Recession (18%, $78). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising. Drivers — implied_target: 77.91; probability: 0.18.
• Base — Pricing-Led Organic Growth (34%, $101). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns. Drivers — implied_target: 100.81; probability: 0.34.
• Growth — Premium Innovation + EM (20%, $127). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 127.28; probability: 0.2.
• Bull — Defensive Re-Rate (8%, $150). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets. Drivers — implied_target: 149.7; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

peer P/E re-rate excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.

Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $83 + scenario PWEV $94, ≈ spot); the weighted blend $80 (-18%) sits below it because the cash-flow DCF ($69) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $83 and 37% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (55% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 7.5%, 13x terminal FCF multiple → $69. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 23.58x) implies $149. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 124% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Consumer Staples — Household

This name sits in the Consumer Staples — Household as a household_personal. branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: PG (household_personal) · CL (household_personal) · KVUE (household_personal) · KMB (household_personal) · EL (household_personal) · CHD (household_personal) · CLX (household_personal)

Mapping note: name-level 'Structural — Private-Label / Brand Erosion' (20%) + 'Consumer / Input Recession' (18%) map to cluster Structural — Private-Label / Brand Erosion (38%); name-level 'Growth — Premium Innovation + EM' (20%) + 'Bull — Defensive Re-Rate' (8%) map to cluster Upside — Premium Innovation / EM (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Structural — Private-Label / Brand Erosion () — this name implies 38% vs the cluster house view of 38% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The staples_household cycle is the shared macro driver. Driver — branded HPC pricing power + organic volume + input costs Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 7.5% · Σ PV(FCF) $3B + PV(terminal) $8B = EV $12B; + net cash → equity $8B ÷ diluted shares 0.12B = $69/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $108/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 13% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $149; EV/Rev → $186.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Household & Personal Care multiple (AI re-rating) (base 15x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-06-30 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1.2% of revenue; cash conversion (OCF/NI) 119% — cash-backed.

Catalyst Calendar

• 2026-07-30 (~22d) — Quarterly earnings — est. EPS $1.64 (AV EARNINGS_CALENDAR)
• 2026-09-15 (~69d) — ERP/digital-transformation go-live milestone and margin-recovery update (authored)
• 2026-11-03 (~118d) — FQ1 2027 results + gross-margin recovery and dividend coverage (authored)
• 2027-02-01 (~208d) — Portfolio-optimisation / divestiture update (non-core brand pruning) (authored)

Forecast Track Record

• EPS surprise: beat 75.0% of the last 8 quarters; average surprise +12.1%.

Competitive Moat

Narrow moat. Clorox has a narrow moat from #1/#2 U.S. share in cleaning/bleach, trash bags (Glad), charcoal (Kingsford) and Burt's Bees - strong domestic brands but a smaller, less-international, more-concentrated portfolio than CL/CHD. The falsifiable test is category volume defence post-pandemic normalisation and after the ERP/cyber disruption; if volumes stay ex-growth and net debt caps reinvestment, the ~15x forward multiple is appropriate and should not re-rate toward the ~23x peer level.

Moat sources:

• FACT: #1/#2 U.S. share in cleaning/disinfecting (Clorox bleach/wipes), trash bags (Glad) and charcoal (Kingsford)
• INFERENCE: brand trust in disinfecting (reinforced during the pandemic) supports pricing, though the volume boost has faded
• ABSENCE: limited international scale and a concentrated, mature category set leave less growth runway than CL/CHD
• ABSENCE: $3.3bn net debt constrains the reinvestment/acquisition flywheel that supports peers' moats

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 15.6× forward EPS, vs the house DCF terminal 13.0×, and a peer median 23.58×. The house DCF sits 29% below spot, so the market is pricing in more than the house case — roughly 2.4pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 18.6× (simple median 23.58×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $85–$127, centre $104 (+7% vs spot); spot sits at the 30th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Defensive Re-Rate): $150.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (40.0); Revenue CAGR ±3pp (25.0); Terminal × ±15% (20.0); WACC ±1pp (8.0); Capex intensity ±15% (8.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 13×, FY+5 revenue $8B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic sales growth (YoY) < 1% (2 consecutive prints → Consumer / Input Recession). Polices the boundary between Base (4% growth) and Consumer / Input Recession (-2%). Two prints below 1% means pricing is no longer offsetting volume and the base case is failing.
• Operating margin (fully loaded) < 13% (2 consecutive prints → Consumer / Input Recession). Midpoint of the Base (14%) and Recession (12%) margin paths. Sustained sub-13% margin signals input-cost and promotional pressure the pricing lever cannot absorb, invalidating the base earnings bridge.
• Organic volume contribution to sales growth < -2% while price/mix remains positive (2 consecutive prints → Structural — Private-Label / Brand Erosion). Volume declining while pricing holds is the trade-down signature: consumers substituting to private label rather than deferring purchases. It distinguishes structural share loss from a cyclical demand pause.
• US tracked-channel share in core categories (bleach, trash bags, wipes, charcoal) declining measurable share loss in 2 or more of the 4 largest categories (2 consecutive prints → Structural — Private-Label / Brand Erosion). The structural scenario's mechanism is private-label substitution in functionally commoditised categories. Broad-based share loss, not a single-category wobble, confirms the brand premium is eroding.
• Net debt / EBITDA > 3.0x (single event → Consumer / Input Recession). Net debt is $3.3bn against roughly $1.3bn of EBITDA (EV/EBITDA 11.3x on EV $14.8bn). Leverage through 3.0x under an earnings downturn would force a choice between the dividend and the buyback, removing the yield support under the equity.

Fact / Inference / Speculation

• FACT: Spot $97; 52-week range $85–$127; engine rating HOLD; base-case target $94 (-3%). (source: Alpha Vantage 2026-06-26, 8 July 2026)
• INFERENCE: Triangulated FV $80 (-18% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Recommendation: HOLD

Balanced: triangulated fair value $88 (-9% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin — a fundamental call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.